Merck announced a sweeping initiative to save $3 billion annually by 2027, redirecting funds from mature products to support new launches and its experimental pipeline. The program involves reductions in administrative, sales, and R&D roles alongside streamlining the manufacturing footprint. The effort responds to challenges including imminent generic competition for Keytruda and a 55% drop in Gardasil sales due to setbacks in major international markets. CEO Rob Davis emphasized reinvestment in growth areas as central to sustaining innovation and shareholder value.